Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SAB01
Therapeutic Area : Dermatology
Study Phase : IND Enabling
Sponsor : GV
Deal Size : $125.0 million
Deal Type : Series B Financing
Santa Ana Bio Launches With $168 Million for Precision Medicines in Inflammatory Diseases
Details : The financing aims to find the advanced pipeline of Santa Ana Bio, which includes SAB01, c-Kit inhibitor. Currently, it is being evaluated for the treatment of urticaria.
Brand Name : SAB01
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 13, 2024
Lead Product(s) : SAB01
Therapeutic Area : Dermatology
Highest Development Status : IND Enabling
Sponsor : GV
Deal Size : $125.0 million
Deal Type : Series B Financing
LOOKING FOR A SUPPLIER?